Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Change in Account Payables of $429251.0 for Q1 2026, down 36.95% year-over-year from $680824.0 in Q1 2025, and down 20.14% quarter-over-quarter from $537526.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Change in Account Payables for 7 consecutive years, with $429251.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 36.95% year-over-year to $429251.0; the TTM figure through Mar 2026 stood at -$104746.0 (down 122.13% YoY), while the FY2025 annual figure was $146827.0, down 45.98% from the prior year.
- Change in Account Payables declined to $429251.0 in Q1 2026 per IKT's latest filing, from $537526.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $911832.0 in Q2 2025 and bottomed at -$2.0 million in Q3 2025.
- Historically, Change in Account Payables has averaged $23814.6 across 5 years, with a median of $54248.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 2415.21% in 2024 and fell as far as 1104.36% in 2024.
- Inhibikase Therapeutics' Change in Account Payables stood at $369950.0 in 2022, then plunged by 123.73% to -$87794.0 in 2023, then slumped by 1104.36% to -$1.1 million in 2024, then soared by 150.84% to $537526.0 in 2025, then declined by 20.14% to $429251.0 in 2026.
- Business Quant data shows IKT's Change in Account Payables at $429251.0 in Q1 2026, $537526.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -625,585.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -625,585.00 |
| Jun 30, 2026 | -625,585.00 |
| Mar 31, 2026 | 429,251.00 |
| Mar 31, 2026 | 429,251.00 |
| Dec 31, 2025 | 537,526.00 |
| Dec 31, 2025 | 537,526.00 |
| Sep 30, 2025 | -1.98 Mn |
| Sep 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | 911,832.00 |
| Jun 30, 2025 | 911,832.00 |
| Mar 31, 2025 | 680,824.00 |
| Mar 31, 2025 | 680,824.00 |
| Dec 31, 2024 | -1.06 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 453,434.00 |
| Sep 30, 2024 | 453,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Mar 31, 2024 | 479,267.00 |
| Mar 31, 2024 | 479,267.00 |